Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis

Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France

(2018) Jérôme Avouac et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Bayesian methods for analysis of biosimilar phase III trials

(2018) Robert E. Weiss et al.   STATISTICS IN MEDICINE

The Science Behind Biosimilars

(2018) S. Louis Bridges et al.   Arthritis & Rheumatology

Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy

(2018) Megan Cann et al.   Pediatric Rheumatology

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

(2018) Bente Glintborg et al.   ANNALS OF THE RHEUMATIC DISEASES

Nocebos in rheumatology: emerging concepts and their implications for clinical practice

(2018) Evrydiki Kravvariti et al.   Nature Reviews Rheumatology

P34 Biosimilar use in children and young people with juvenile idiopathic arthritis in a real-world setting in the United Kingdom

(2018) Diederik Decock et al.   RHEUMATOLOGY

Healthcare professionals’ perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study

(2018) Mohammed Ibrahim Aladul et al.   BMJ Open

Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis

(2017) Yuga Komaki et al.   JOURNAL OF AUTOIMMUNITY

Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis

(2017) Athimalaipet V. Ramanan et al.   NEW ENGLAND JOURNAL OF MEDICINE

The process defines the product: what really matters in biosimilar design and production?

(2017) Arnold G. Vulto et al.   RHEUMATOLOGY

Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab

(2017) Lieke Tweehuysen et al.   Arthritis & Rheumatology

Psychological Placebo and Nocebo Effects on Pain Rely on Expectation and Previous Experience

(2016) Philipp Reicherts et al.   JOURNAL OF PAIN

Biosimilars in rheumatology: understanding the rigor of their development

(2016) Niti Goel et al.   RHEUMATOLOGY

The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort

(2014) Jaime Guzman et al.   ANNALS OF THE RHEUMATIC DISEASES

Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars?

(2013) Howard Lee   AAPS Journal

Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis

(2008) Daniel J. Lovell et al.   NEW ENGLAND JOURNAL OF MEDICINE